Ginkgo Bioworks Holdings (DNA) Enterprise Value (2019 - 2026)
Ginkgo Bioworks Holdings' (DNA) quarterly Enterprise Value came in at -$143.9 million in Q1 2026, up 53.95% YoY from -$93.4 million in Q1 2025, and up 65.96% on a QoQ basis from -$422.6 million in Q4 2025.
Ginkgo Bioworks Holdings (DNA) Enterprise Value (2019 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings (DNA) has 8 years of Enterprise Value data on file, last reported at -$143.9 million in Q1 2026.
- Quarterly Enterprise Value rose 53.95% year-over-year to -$143.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$143.9 million (up 53.95% YoY) and the FY2025 annual result came in at -$422.6 million, up 24.74% from the prior year.
- Enterprise Value improved to -$143.9 million in Q1 2026, from -$422.6 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$111.1 million in Q3 2025 to a low of -$1.5 billion in Q1 2022.
- A 5-year average of -$805.0 million and a median of -$840.4 million in 2024 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2022 — Enterprise Value slumped 472.73% — and 2025, when it surged 81.98%.
- Tracing DNA's Enterprise Value over 5 years: stood at -$1.3 billion in 2022, then rose by 28.36% to -$944.1 million in 2023, then surged by 40.52% to -$561.6 million in 2024, then grew by 24.74% to -$422.6 million in 2025, then soared by 65.96% to -$143.9 million in 2026.
- The last three Enterprise Value figures came in at -$143.9 million (Q1 2026), -$422.6 million (Q4 2025), and -$111.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Ginkgo Bioworks Holdings | 432.60 Mn | 348.06 Mn | 18.44 Mn | -84.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -84.54 Mn |
| Mar 31, 2026 | -143.86 Mn |
| Dec 31, 2025 | -422.62 Mn |
| Sep 30, 2025 | -111.07 Mn |
| Jun 30, 2025 | -203.57 Mn |
| Mar 31, 2025 | -312.42 Mn |
| Dec 31, 2024 | -561.57 Mn |
| Sep 30, 2024 | -616.21 Mn |
| Jun 30, 2024 | -730.37 Mn |
| Mar 31, 2024 | -840.44 Mn |
| Dec 31, 2023 | -944.07 Mn |
| Sep 30, 2023 | -1.05 Bn |
| Jun 30, 2023 | -1.11 Bn |
| Mar 31, 2023 | -1.21 Bn |
| Dec 31, 2022 | -1.32 Bn |
| Sep 30, 2022 | -1.30 Bn |
| Jun 30, 2022 | -1.35 Bn |
| Mar 31, 2022 | -1.47 Bn |
| Dec 31, 2021 | -1.50 Bn |
| Sep 30, 2021 | -1.68 Bn |